Your browser doesn't support javascript.
loading
Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo.
Akhmedov, Alexander; Rozenberg, Izabela; Paneni, Francesco; Camici, Giovanni G; Shi, Yi; Doerries, Carola; Sledzinska, Anna; Mocharla, Pavani; Breitenstein, Alexander; Lohmann, Christine; Stein, Sokrates; von Lukowicz, Tobias; Kurrer, Michael O; Borén, Jan; Becher, Burkhard; Tanner, Felix C; Landmesser, Ulf; Matter, Christian M; Lüscher, Thomas F.
Afiliação
  • Akhmedov A; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Rozenberg I; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Paneni F; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Camici GG; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Shi Y; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Doerries C; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Sledzinska A; Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland Neuroimmunology Unit, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Mocharla P; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Breitenstein A; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Lohmann C; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Stein S; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • von Lukowicz T; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Kurrer MO; Division of Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Borén J; Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Göteborg, Gothenburg, Sweden.
  • Becher B; Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland Neuroimmunology Unit, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Tanner FC; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Landmesser U; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Matter CM; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Lüscher TF; Cardiovascular Research, Institute of Physiology, University of Zurich; and Cardiovascular Center, Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland cardiotfl@gmx.ch.
Eur Heart J ; 35(40): 2839-48, 2014 Oct 21.
Article em En | MEDLINE | ID: mdl-24419805
ABSTRACT

AIMS:

Lectin-like oxLDL receptor-1 (LOX-1) mediates the uptake of oxidized low-density lipoprotein (oxLDL) in endothelial cells and macrophages. However, the different atherogenic potential of LOX-1-mediated endothelial and macrophage oxLDL uptake remains unclear. The present study was designed to investigate the in vivo role of endothelial LOX-1 in atherogenesis. METHODS AND

RESULTS:

Endothelial-specific LOX-1 transgenic mice were generated using the Tie2 promoter (LOX-1TG). Oxidized low-density lipoprotein uptake was enhanced in cultured endothelial cells, but not in macrophages of LOX-1TG mice. Six-week-old male LOX-1TG and wild-type (WT) mice were fed a high-cholesterol diet (HCD) for 30 weeks. Increased reactive oxygen species production, impaired endothelial nitric oxide synthase activity and endothelial dysfunction were observed in LOX-1TG mice as compared with WT littermates. LOX-1 overexpression led to p38 phosphorylation, increased nuclear factor κB activity and subsequent up-regulation of vascular cell adhesion molecule-1, thereby favouring macrophage accumulation and aortic fatty streaks. Consistently, HCD-fed double-mutant LOX-1TG/ApoE(-/-) displayed oxidative stress and vascular inflammation with higher aortic plaques than ApoE(-/-) controls. Finally, bone marrow transplantation experiments showed that endothelial LOX-1 was sufficient for atherosclerosis development in vivo.

CONCLUSIONS:

Endothelial-specific LOX-1 overexpression enhanced aortic oxLDL levels, thereby favouring endothelial dysfunction, vascular inflammation and plaque formation. Thus, LOX-1 may serve as a novel therapeutic target for atherosclerosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endotélio Vascular / Aterosclerose / Receptores Depuradores Classe E Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: Eur Heart J Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endotélio Vascular / Aterosclerose / Receptores Depuradores Classe E Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: Eur Heart J Ano de publicação: 2014 Tipo de documento: Article